Published in Nat Genet on February 13, 2011
Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature (2011) 7.03
JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proc Natl Acad Sci U S A (2012) 1.88
Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell (2013) 1.86
Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. Nat Commun (2015) 1.79
Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas. Science (2014) 1.53
A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway. Nat Cell Biol (2013) 1.41
ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis. Cell Death Differ (2014) 1.18
JNK signalling in cancer: in need of new, smarter therapeutic targets. Br J Pharmacol (2014) 1.11
FOXP3 Controls an miR-146/NF-κB Negative Feedback Loop That Inhibits Apoptosis in Breast Cancer Cells. Cancer Res (2015) 1.08
New insights into oncogenic stress. Nat Genet (2011) 1.07
Molecular mechanisms of liver injury and hepatocarcinogenesis: focusing on the role of stress-activated MAPK. Patholog Res Int (2012) 1.04
Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis. J Clin Invest (2014) 1.04
The 2 Faces of JNK Signaling in Cancer. Genes Cancer (2013) 1.00
TPL2 kinase is a suppressor of lung carcinogenesis. Proc Natl Acad Sci U S A (2013) 0.99
MKK7 and ARF: new players in the DNA damage response scenery. Cell Cycle (2014) 0.86
Role of Gadd45a in Wip1-dependent regulation of intestinal tumorigenesis. Cell Death Differ (2012) 0.81
Impaired JNK signaling cooperates with KrasG12D expression to accelerate pancreatic ductal adenocarcinoma. Cancer Res (2014) 0.81
Involvement of free radicals in breast cancer. Springerplus (2013) 0.80
Co-Targeting of JNK and HUNK in Resistant HER2-Positive Breast Cancer. PLoS One (2016) 0.80
Eyelid closure in embryogenesis is required for ocular adnexa development. Invest Ophthalmol Vis Sci (2014) 0.80
Involvement of stress kinase mitogen-activated protein kinase kinase 7 in regulation of mammalian circadian clock. J Biol Chem (2012) 0.80
In vivo gene manipulation reveals the impact of stress-responsive MAPK pathways on tumor progression. Cancer Sci (2015) 0.79
Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis. Cancer Res (2015) 0.78
NF-κB1 p105 suppresses lung tumorigenesis through the Tpl2 kinase but independently of its NF-κB function. Oncogene (2015) 0.78
Conditional expression of oncogenic C-RAF in mouse pulmonary epithelial cells reveals differential tumorigenesis and induction of autophagy leading to tumor regression. Neoplasia (2011) 0.78
The MKK7 p.Glu116Lys Rare Variant Serves as a Predictor for Lung Cancer Risk and Prognosis in Chinese. PLoS Genet (2016) 0.78
JNK/SAPK Signaling Is Essential for Efficient Reprogramming of Human Fibroblasts to Induced Pluripotent Stem Cells. Stem Cells (2016) 0.77
ZPK/DLK and MKK4 form the critical gateway to axotomy-induced motoneuron death in neonates. J Neurosci (2014) 0.77
IL-15 suppresses colitis-associated colon carcinogenesis by inducing antitumor immunity. Oncoimmunology (2015) 0.77
Neddylation controls basal MKK7 kinase activity in breast cancer cells. Oncogene (2015) 0.77
The putative tumor suppressor gene EphA3 fails to demonstrate a crucial role in murine lung tumorigenesis or morphogenesis. Dis Model Mech (2015) 0.76
mTORC1 senses stresses: Coupling stress to proteostasis. Bioessays (2017) 0.75
JNK1/2 expression and modulation of STAT3 signaling in oral cancer. Oncol Lett (2016) 0.75
Cancer biology: Enzyme meets a surprise target. Nature (2014) 0.75
Expression of signaling components in embryonic eyelid epithelium. PLoS One (2014) 0.75
Novel tumor suppressor function of KLF4 in pediatric T-cell acute lymphoblastic leukemia. Exp Hematol (2017) 0.75
Age-dependent motor dysfunction due to neuron-specific disruption of stress-activated protein kinase MKK7. Sci Rep (2017) 0.75
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature (2005) 18.30
Tumor spectrum analysis in p53-mutant mice. Curr Biol (1994) 16.60
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev (2001) 15.97
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature (2005) 14.65
Lung cancer. N Engl J Med (2008) 13.49
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature (2006) 11.76
Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature (2006) 11.18
Tumour biology: senescence in premalignant tumours. Nature (2005) 10.15
Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer (2009) 9.33
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med (1996) 7.32
The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res (2005) 5.93
The JNK signal transduction pathway. Curr Opin Cell Biol (2007) 5.86
Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev (2001) 5.67
Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell (2003) 5.17
Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res (1997) 4.89
"Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J (2002) 4.17
Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer (2009) 4.06
Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell (2003) 3.92
Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev (1999) 3.51
Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res (2004) 3.43
Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet (2001) 3.27
Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development. Nature (2005) 3.05
JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development. Curr Biol (1999) 2.60
c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev Cell (2003) 2.59
MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines. Genes Dev (2001) 2.48
Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci U S A (2000) 2.41
JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev (1998) 2.29
p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res (1991) 2.09
Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med (1998) 2.08
Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice. Cancer Res (2001) 2.00
The MAPK(ERK-1,2) pathway integrates distinct and antagonistic signals from TGFalpha and FGF7 in morphogenesis of mouse mammary epithelium. Dev Biol (2007) 1.98
c-Jun NH2-terminal kinase (JNK)1 and JNK2 have similar and stage-dependent roles in regulating T cell apoptosis and proliferation. J Exp Med (2001) 1.81
Requirement for Rac1 in a K-ras induced lung cancer in the mouse. Cancer Res (2007) 1.80
Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res (2002) 1.77
Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas. Nat Biotechnol (2009) 1.76
JNK signalling modulates intestinal homeostasis and tumourigenesis in mice. EMBO J (2009) 1.74
p53 mutations in breast cancer. Cancer Res (1992) 1.73
Suppression of p53-dependent senescence by the JNK signal transduction pathway. Proc Natl Acad Sci U S A (2007) 1.67
Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol Cell Biol (2001) 1.54
Suppression of Ras-stimulated transformation by the JNK signal transduction pathway. Genes Dev (2003) 1.48
Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphorylation. Oncogene (2000) 1.45
Tissue-specific p19Arf regulation dictates the response to oncogenic K-ras. Proc Natl Acad Sci U S A (2010) 1.28
Cooperation between JNK1 and JNK2 in activation of p53 apoptotic pathway. Oncogene (2007) 1.26
Limited role of murine ATM in oncogene-induced senescence and p53-dependent tumor suppression. PLoS One (2009) 1.22
JNK1, JNK2 and JNK3 are p53 N-terminal serine 34 kinases. Oncogene (1997) 1.20
The c-Jun NH2-terminal kinase is essential for epidermal growth factor expression during epidermal morphogenesis. Proc Natl Acad Sci U S A (2004) 1.19
Identification and characterization of rodent ABCA1 in isolated type II pneumocytes. Am J Physiol Lung Cell Mol Physiol (2003) 1.10
Precancerous lesions of the breast. Nat Clin Pract Oncol (2008) 0.96
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature (2005) 14.65
The hallmarks of aging. Cell (2013) 14.29
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature (2006) 11.76
An oncogene-induced DNA damage model for cancer development. Science (2008) 11.60
Tumour biology: senescence in premalignant tumours. Nature (2005) 10.15
Cerebral organoids model human brain development and microcephaly. Nature (2013) 9.07
Cellular senescence in cancer and aging. Cell (2007) 9.04
A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature (2009) 7.96
Systemic spread is an early step in breast cancer. Cancer Cell (2008) 7.91
The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature (2009) 7.39
Genomic instability--an evolving hallmark of cancer. Nat Rev Mol Cell Biol (2010) 7.11
Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand breaks. Nature (2004) 6.72
Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell (2008) 6.37
Senescence in tumours: evidence from mice and humans. Nat Rev Cancer (2010) 6.34
Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med (2011) 5.66
Regulation of cancer cell migration and bone metastasis by RANKL. Nature (2006) 5.27
Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A (2008) 5.21
Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell (2003) 5.17
A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev (2007) 5.07
Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature (2002) 5.02
Mitogen-activated protein kinases in apoptosis regulation. Oncogene (2004) 4.76
Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells. Cell Stem Cell (2009) 4.59
An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35
Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell (2002) 4.35
The common biology of cancer and ageing. Nature (2007) 4.28
"Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J (2002) 4.17
The adaptor protein CARD9 is essential for the activation of myeloid cells through ITAM-associated and Toll-like receptors. Nat Immunol (2007) 4.12
Electrical signals control wound healing through phosphatidylinositol-3-OH kinase-gamma and PTEN. Nature (2006) 4.09
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01
Delayed ageing through damage protection by the Arf/p53 pathway. Nature (2007) 3.87
Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell (2007) 3.82
Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature (2002) 3.74
RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med (2005) 3.68
Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood (2003) 3.47
Identifying the MAGUK protein Carma-1 as a central regulator of humoral immune responses and atopy by genome-wide mouse mutagenesis. Immunity (2003) 3.36
RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol (2001) 3.27
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med (2005) 3.26
Mature-onset obesity and insulin resistance in mice deficient in the signaling adapter p62. Cell Metab (2006) 3.22
The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell (2013) 3.19
AIF deficiency compromises oxidative phosphorylation. EMBO J (2004) 3.19
Control of cell polarity and motility by the PtdIns(3,4,5)P3 phosphatase SHIP1. Nat Cell Biol (2006) 3.19
New gene functions in megakaryopoiesis and platelet formation. Nature (2011) 3.14
Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature (2005) 3.09
Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med (2006) 3.09
Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun (2010) 2.97
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med (2013) 2.93
RANK signals from CD4(+)3(-) inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla. J Exp Med (2007) 2.91
Drosophila genome-wide obesity screen reveals hedgehog as a determinant of brown versus white adipose cell fate. Cell (2010) 2.91
The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol (2004) 2.90
The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer (2006) 2.85
Telomerase reverse transcriptase delays aging in cancer-resistant mice. Cell (2008) 2.85
The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. Immunity (2008) 2.81
Programmed cell senescence during mammalian embryonic development. Cell (2013) 2.78
Seventy-five genetic loci influencing the human red blood cell. Nature (2012) 2.77
Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity (2004) 2.76
Forward and reverse genetics through derivation of haploid mouse embryonic stem cells. Cell Stem Cell (2011) 2.69
Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. J Clin Invest (2003) 2.68
The MAGUK family protein CARD11 is essential for lymphocyte activation. Immunity (2003) 2.67
The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell (2004) 2.65
The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. Immunity (2008) 2.57
Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell (2011) 2.56
ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature (2012) 2.53
Oncogenic activity of Cdc6 through repression of the INK4/ARF locus. Nature (2006) 2.51
Genome-wide RNAi screen identifies genes involved in intestinal pathogenic bacterial infection. Science (2009) 2.47
Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature (2013) 2.47
Epigenetic regulation of Nanog expression by Ezh2 in pluripotent stem cells. Cell Cycle (2011) 2.45
A mammalian microRNA cluster controls DNA methylation and telomere recombination via Rbl2-dependent regulation of DNA methyltransferases. Nat Struct Mol Biol (2008) 2.43
Depletion of ribosomal protein L37 occurs in response to DNA damage and activates p53 through the L11/MDM2 pathway. Cell Cycle (2010) 2.41
T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17. J Exp Med (2006) 2.38
A genome-wide Drosophila screen for heat nociception identifies α2δ3 as an evolutionarily conserved pain gene. Cell (2010) 2.37
The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism. Cell Metab (2012) 2.36
Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. Hepatology (2011) 2.33
A global in vivo Drosophila RNAi screen identifies NOT3 as a conserved regulator of heart function. Cell (2010) 2.27
p53: guardian of the genome and policeman of the oncogenes. Cell Cycle (2007) 2.23
Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development. Sci Signal (2008) 2.19
Impact of ACE2 deficiency and oxidative stress on cerebrovascular function with aging. Stroke (2012) 2.18
A minimally invasive assay for individual assessment of the ATM/CHEK2/p53 pathway activity. Cell Cycle (2011) 2.13
RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci (2008) 2.10
SIRT1: recent lessons from mouse models. Nat Rev Cancer (2010) 2.07
Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med (2003) 2.04
Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol (2002) 2.04
Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int (2008) 1.99
Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin. Cancer Res (2007) 1.97